- Home
- PBYI vs LPRO Comparison
PBYI vs LPRO Comparison
Compare PBYI & LPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- LPRO
- Stock Information
- Founded
- PBYI 2010
- LPRO 2000
- Country
- PBYI United States
- LPRO United States
- Employees
- PBYI N/A
- LPRO N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- LPRO Finance: Consumer Services
- Sector
- PBYI Health Care
- LPRO Finance
- Exchange
- PBYI Nasdaq
- LPRO Nasdaq
- Market Cap
- PBYI 138.4M
- LPRO 124.6M
- IPO Year
- PBYI N/A
- LPRO N/A
- Fundamental
- Price
- PBYI $2.91
- LPRO $1.74
- Analyst Decision
- PBYI Strong Buy
- LPRO Buy
- Analyst Count
- PBYI 1
- LPRO 7
- Target Price
- PBYI $7.00
- LPRO $3.44
- AVG Volume (30 Days)
- PBYI 280.0K
- LPRO 3.7M
- Earning Date
- PBYI 05-08-2025
- LPRO 05-07-2025
- Dividend Yield
- PBYI N/A
- LPRO N/A
- EPS Growth
- PBYI 143.51
- LPRO N/A
- EPS
- PBYI 0.77
- LPRO N/A
- Revenue
- PBYI $232,668,000.00
- LPRO $17,672,000.00
- Revenue This Year
- PBYI N/A
- LPRO $320.95
- Revenue Next Year
- PBYI N/A
- LPRO $6.76
- P/E Ratio
- PBYI $3.78
- LPRO N/A
- Revenue Growth
- PBYI 2.67
- LPRO N/A
- 52 Week Low
- PBYI $2.23
- LPRO $0.70
- 52 Week High
- PBYI $5.20
- LPRO $6.97
- Technical
- Relative Strength Index (RSI)
- PBYI 44.50
- LPRO 54.41
- Support Level
- PBYI $2.88
- LPRO $1.24
- Resistance Level
- PBYI $3.14
- LPRO $1.42
- Average True Range (ATR)
- PBYI 0.16
- LPRO 0.17
- MACD
- PBYI 0.00
- LPRO 0.18
- Stochastic Oscillator
- PBYI 11.36
- LPRO 84.70
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.